Related Experiment Videos
Pulmonary disease in the immunocompromised host. 1
Abstract:
With few exceptions, pulmonary complications in the immunocompromised host will proceed to death unless the clinician intercedes. The differential diagnosis of diffuse pulmonary disease in this setting includes (1) infection, most commonly from opportunistic organisms; (2) recurrence or extension of the basic underlying disease process to involve the lungs; (3) adverse pulmonary reaction to drugs; (4) a new, unrelated disease process such as cardiac pulmonary edema or pulmonary emboli; and (5) any combination of these categories. Up to a third of these patients have two or more complications, such as pneumonitis from two different opportunistic organisms or an opportunistic infection and a drug-induced pulmonary complication. An understanding of the host defense that is compromised enables the clinician to narrow the differential diagnosis. The most common types of impairment of defense mechanisms are reductions in the number of granulocytes, B-lymphocytes, or T-lymphocytes, and not uncommonly, two or all three of these types of cells are involved. Impairment of each of these cell types is associated with an increased frequency of infection by a particular group of organisms. Consequently, the clinician can be somewhat selective if empiric therapy is being considered. In the immunocompromised patient, most pulmonary complications, including drug-induced pulmonary disease and pulmonary emboli, are associated with fever that mimics an infection. Up to 25% of the pulmonary complications in these patients are noninfectious.
Insights
Pulmonary complications in immunocompromised patients are often fatal without intervention. Understanding compromised host defenses, like reduced granulocytes or lymphocytes, helps narrow the diagnosis for effective treatment.
Area of Science:
- Pulmonology
- Immunology
- Oncology
Background:
- Pulmonary complications are a leading cause of mortality in immunocompromised patients.
- Prompt clinical intervention is crucial for managing diffuse pulmonary disease in this population.
- Differential diagnosis includes infection, disease recurrence, drug reactions, and unrelated conditions.
Purpose of the Study:
- To outline the differential diagnosis of diffuse pulmonary disease in immunocompromised hosts.
- To emphasize the importance of understanding host defense mechanisms in guiding diagnosis and treatment.
- To highlight the frequency of multiple concurrent pulmonary complications.
Main Methods:
- Review of clinical presentations and diagnostic challenges in immunocompromised patients with pulmonary disease.
- Analysis of common host defense impairments (granulocyte, B-lymphocyte, T-lymphocyte deficiencies).
- Categorization of pulmonary complications, including infectious and non-infectious causes.
Main Results:
- Diffuse pulmonary disease in immunocompromised hosts has a broad differential diagnosis.
- Impaired host defenses (granulocytopenia, lymphocytopenia) correlate with specific opportunistic infections.
- Up to one-third of patients experience multiple pulmonary complications.
- Non-infectious pulmonary complications, including drug-induced disease and pulmonary emboli, occur in up to 25% of cases.
Conclusions:
- Understanding the specific type of host defense impairment aids in narrowing the differential diagnosis.
- Empiric therapy can be guided by knowledge of which organisms are associated with specific immune deficiencies.
- Recognizing non-infectious causes is critical, as they often mimic infections and are frequently associated with fever.